Delivery Order SPE2DB20D2001-SPE2DB25FPNNY
- Not listed
- The Defense Logistics Agency awarded a $39,518.60 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Somatuline Depot 120 mg/0.5 ml injectable medication, with a completion date of September 15, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $39,518.60 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Somatuline Depot 120 mg/0.5 ml pharmaceutical product, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Somatuline Depot 120 mg/0.5 mL pharmaceutical product. This firm fixed-price delivery order, valued at $3,951.86, represents a non-set-aside competitive award with an ultimate completion date of August 28, 2025. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,616.51 for Somatuline Depot 90 mg/0.3 ml pharmaceutical product on August 4, 2025, with completion targeted for August 25, 2025. This is a firm fixed price, non-set-aside delivery order to be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $11,233.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Somatuline Depot 90 mg/0.3 ml pharmaceutical product on August 12, 2025, with completion expected by September 3, 2025. This competitively awarded, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 29, 2025, for the supply of Somatuline Depot 90 mg/0.3 ml injectable medication, with a ceiling value of $5,616.51. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics...
- The Defense Logistics Agency awarded a $21,022.20 delivery order to AmerisourceBergen Drug Corp for Somatuline Depot 60 mg/0.2 ml pharmaceutical product on August 15, 2025, with completion scheduled for September 8, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitive award through the company's existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $3,951.86 delivery order to AmerisourceBergen Drug Corp for Somatuline Depot 120 mg/0.5 ml pharmaceutical product, with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on August 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical...
- The U.S. Department of Defense (DoD) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Somatuline Depot 120 mg/0.5 ml pharmaceuticals. The contract, valued at $2,896.41, has an ultimate completion date of April 2, 2024. This delivery order is issued under an indefinite delivery contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical, which serves as the primary...
- AmerisourceBergen Drug Corp was awarded a $3,951.86 firm fixed-price delivery order on August 18, 2025, for Somatuline Depot 120 mg/0.5 ml pharmaceutical product, with an ultimate completion date of September 9, 2025. The contract is unclassified as to set-aside designation and is being performed in Conshohocken, Pennsylvania. This delivery order is funded by the Defense Logistics Agency's Medical Supply Chain and represents a child contract under AmerisourceBergen's larger indefinite delivery...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNNYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Somatuline Depot 90 mg/0.3 ml injectable medication. This firm fixed-price delivery order, valued at $11,233.02, represents a non-competitive child award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion blanket agreement running through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with delivery expected by September 16, 2025. Somatuline Depot is a specialty pharmaceutical used in the treatment of acromegaly and neuroendocrine tumors, indicating this procurement supports the military healthcare supply chain for specialized patient care needs. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp regularly fulfills delivery orders through its DLA prime contract to supply brand-name and generic medications, vaccines, and medical supplies to Defense Health Agency and military healthcare systems worldwide. This delivery order exemplifies the company's role in providing essential specialty pharmaceuticals to support military medical operations and beneficiary care. The award carries no set-aside designation, and completion is scheduled for mid-September 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 8/25/25 |